Broadcom Inc. vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines Broadcom Inc. and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Broadcom Inc. on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Broadcom Inc. and Cardinal Health, Inc. is widest.

On the headline numbers, Broadcom Inc. reports annual revenue of $63.9B against $254.2B for Cardinal Health, Inc., while their respective market capitalizations stand at $1.68T and $56.0B. Both Broadcom Inc. and Cardinal Health, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Broadcom Inc.: Much of the internet runs on Broadcom parts that users never see. Its chips route traffic inside cloud data centers, connect phones and laptops to Wi-Fi, and run cable and fiber gateways, while its VMware software runs a large share of corporate private clouds. Since 2024 the company's identity has shifted toward AI: custom accelerators and AI networking went from about $12 billion of revenue in fiscal 2024 to $16.7 billion in a single quarter in 2026.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Broadcom Inc. and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Broadcom Inc. and Cardinal Health, Inc..

Broadcom Inc. business model: Broadcom reports two segments. Semiconductor Solutions sold $36.9 billion of chips in fiscal 2025: custom AI accelerators (XPUs) designed with hyperscale customers, Tomahawk and Jericho Ethernet switch chips, network adapters, optical components, Wi-Fi and Bluetooth chips, RF filters for smartphones, broadband gateway chips and storage connectivity. Infrastructure Software brought in $27.0 billion, mostly VMware Cloud Foundation subscriptions plus mainframe, security and automation software from CA and Symantec. Most advanced chips are made by outside foundries, chiefly TSMC. The mix is moving quickly toward AI: in the third quarter of fiscal 2026 semiconductors were 70% of revenue, and AI chips alone were $16.7 billion of the $29.6 billion total.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Broadcom Inc. stack up against those of Cardinal Health, Inc..

Broadcom Inc. competitive advantage: Broadcom's edge is engineering depth in a few hard problems where customers rarely switch once a design is chosen: high-speed SerDes, switch silicon, advanced packaging and custom ASIC design. Its Tomahawk 6 switch chip, announced in June 2025, handles 102.4 terabits per second. In software, VMware is built into enterprise data centers, which makes migrations slow and costly. Scale reinforces both: fiscal 2025 free cash flow of $26.9 billion pays for R&D, dividends and debt reduction at the same time.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Future prospects matter as much as current results. The growth strategies below explain how Broadcom Inc. and Cardinal Health, Inc. each plan to expand from here.

Broadcom Inc. growth strategy: Broadcom's growth plan has two engines. In chips, it co-designs custom accelerators with a short list of customers, including Google's TPU, Meta's MTIA, OpenAI and Anthropic, and sells the Ethernet switches, network adapters and optics that connect them. In software, it is moving VMware's installed base onto VMware Cloud Foundation subscriptions; VCF 9.0 shipped in June 2025 as a private-cloud alternative to the public cloud, and infrastructure software revenue rose 29% to $8.8 billion in the third quarter of fiscal 2026. Acquisitions, the historic third engine, have been on hold while VMware debt is paid down.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

A closer look at the financial trajectory of Broadcom Inc. and Cardinal Health, Inc. rounds out the comparison.

Broadcom Inc.: Fiscal 2025 revenue rose 24% to $63.9 billion and net income reached $23.1 billion, up from $5.9 billion in fiscal 2024, when a large income tax charge weighed on results. Operating income was $25.5 billion and free cash flow $26.9 billion, of which $11.1 billion went to dividends and $6.4 billion to buybacks. Fiscal 2026 then accelerated: quarterly revenue went from $19.3 billion in Q1 to $22.2 billion in Q2 and $29.6 billion in Q3, with Q4 guided at about $34.8 billion. Long-term debt taken on for VMware fell to $57.2 billion at 2 August 2026 from $62.0 billion at the end of fiscal 2025, and the quarterly dividend is $0.65 a share after a 10% increase.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.